Keywords: king, pharma, returns, bremelanotide, rights, palatin, technologies

King Pharma returns bremelanotide rights to Palatin

Article | 17 September 2007

Print This

Palatin Technologies says it has re-acquired full rights to bremelanotide, a first in class melanocortin agonist drug candidate for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in